The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
Abstract
Purpose: Imatinib is remarkably effective in treating newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come from a single multicenter study in which some of the patients were censored for diverse reasons. Here, we report our experience in treating patients at a single institution in a setting where all events were recorded. Patients and Methods: A total of 204 consecutive adult patients with newly diagnosed CML in CP received imatinib from June 2000 until August 2006. Response (hematologic, cytogenetic, and molecular), progression-free survival (PFS) and survival were evaluated. Results: At 5 years, cumulative incidences of complete cytogenetic response (CCyR) and major molecular response (MMR) were 82.7% and 50.1%, respectively. Estimated overall survival and PFS were 83.2% and 82.7%, respectively. By 5 years, 25% of patients had discontinued imatinib treatment because of an unsatisfactory response and/or toxicity. The 5-year probability of remaining in major cytogenetic response while still receiving imatinib was 62.7%. Patients achieving a CCyR at 1 year had a better PFS and overall survival than those failing to reach CCyR, but achieving a MMR conferred no further advantage. The identification of a kinase domain mutation was the only factor predicting for loss of CCyR. Conclusion: Imatinib is highly effective in most patients with CML-CP; patients who respond are likely to live substantially longer than those treated with earlier therapies. Achieving CCyR correlated with PFS and overall survival, but achieving MMR had no further predictive value. However, approximately one third of patients still need better therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Self-citationPrognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
Self-citationSoverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1516 · Cited by 511
Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., Zhou, X., Luthra, R., Garcia-Manero, G., Giles, F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404318 · Cited by 386
Canellos, G. P. (1976) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31845-4 · Cited by 343
Characteristics of accelerated disease in chronic myelogenous leukemia
Kantarjian, H. M., Dixon, D., Keating, M. J., Talpaz, M., Walters, R. S., McCredie, K. B., & Freireich, E. J. (1988) · Cancer · doi:10.1002/1097-0142(19880401)61:7<1441::aid-cncr2820610727>3.0.co;2-c · Cited by 270
Roy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B. J., Larson, R. A., O'Brien, S., So, C., Massimini, G., & Guilhot, F. (2006) · Blood · doi:10.1182/blood-2006-02-001495 · Cited by 216
Kantarjian, H. M., Talpaz, M., O'Brien, S., Jones, D., Giles, F., Garcia-Manero, G., Faderl, S., Ravandi, F., Rios, M. B., Shan, J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004325 · Cited by 208
Khorashad, J. S., Anand, M., Marin, D., Saunders, S., Al-Jabary, T., Iqbal, A., Margerison, S., Melo, J. V., Goldman, J. M., Apperley, J. F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404137 · Cited by 149
Self-citationPress, R. D., Galderisi, C., Yang, R., Rempfer, C., Willis, S. G., Mauro, M. J., Druker, B. J., & Deininger, M. W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1112 · Cited by 126
Kaeda, J., O’Shea, D., Szydlo, R., Olavarría, E., Dazzi, F., Marin, D., Saunders, S. E., Khorashad, J. S., Cross, N. C. P., Goldman, J. M., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3320 · Cited by 122
Self-citationMarktel, S., Marín, D., Foot, N. J., Szydlo, R., Bua, M., Karadimitris, A., Melo, V. A. S. D., Kotzampaltiris, P., Dazzi, F., Rahemtulla, A., et al. (2003) · PubMed · Cited by 102
Self-citationCytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia
Kaeda, J., Chase, A., & Goldman, J. M. (2002) · Acta Haematologica · doi:10.1159/000046635 · Cited by 88
Self-citationMarín, D., Marktel, S., Szydlo, R., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14182-7 · Cited by 35
Self-citationImatinib in Chronic Myeloid Leukemia
Krause, S. W., & Holler, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmc063767 · Cited by 5
Cited by
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Mahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citation
Metadata
- Authors
- de Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., & Marin, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-10
- Volume
- 26
- Issue
- 20
- Pages
- 3358-3363
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158884958
- Cited by
- 551
- References
- 24
- FWCI
- 34.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.